Registry Study of T Cell Depleted Allo Non-Myeloablative Stem Cell Transplant

Conditions:Blood Cancer, Blood Cancer, Blood Cancer, Lymphoma, Lymphoma, Hematology, Leukemia
Therapuetic Areas:Hematology, Oncology
Age Range:18 - Any
Start Date:August 2013
End Date:July 2030
Contact:David A Rizzieri, MD

Use our guide to learn which trials are right for you!

Registry Study of T Cell Depleted Allogeneic Non-Myeloablative Stem Cell Transplant Recipients

Allogeneic transplantation is used to treat many malignant and non-malignant diseases. The
investigators and others have shown that less toxic preparative regimens (reduced intensity
or 'mini' transplants) allow reliable allogeneic engraftment and durable remissions,
significantly broadening the population of patients who may be offered this therapy to those
who are older and more infirmed. The field is now focusing on the period post transplant for
approaches to immune recovery leading to improved outcomes.

The primary objective of this registry is to catalogue data from patients who undergo
standard of care reduced intensity allogeneic transplantation.

Subjects will have toxicity monitored and reported per the Center for International Blood
and Marrow Transplant Research (CIBMTR) program standard and as required by law for bone
marrow transplant (BMT) reporting in the USA. Data will be collected from physical exam,
laboratory studies, radiographs that are performed for clinical purposes. The tests and
procedures are not in addition or in excess of our standards for allogeneic transplant
outside of this registry. Data about donors will also be collected.

Recipient Inclusion Criteria:

- Subjects ≥ 18 years of age undergoing a reduced intensity allogeneic transplant

Exclusion Criteria:

- Subjects < 18 years of age

- Subjects not undergoing nonmyeloablative or ablative allogeneic transplant
We found this trial at
Durham, North Carolina
Principal Investigator: David Rizzieri, MD
Phone: 919-684-7115
Durham, NC
Click here to add this to my saved trials